
ATMPs Pharmacy Training Session

Organisation: iMATCH, University of Manchester NHS Foundation Trust

Document version number: 1

Date written: October 2018

End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

Attributions: Name of Organisation; [others as required by Organisation to be listed here]

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here:

<https://creativecommons.org/licenses/by-nc/4.0/>

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or

Funded by

Coordinated by

death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.

We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents. The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Funded by

Coordinated by




Advance Therapy Medicinal Products (ATMPs) Pharmacy Teaching Session

Autumn 2018

Nisa Khan


Overview

- Definitions
- Why now?
- Pipeline
- iMATCH
- Impact of ATMPs for Pharmacy
 - Governance
 - Management of toxicity
- Clinical Trials
- Licensed Products
- Summary



Advanced Therapy
Medicinal Products
(ATMPs) are one of three
types of medicine

- Gene Therapy Medicines
- Somatic Cell Therapy Medicines
- Tissue Engineered Medicines



Tissue-engineered medicines:

Contain cells or tissues that have been modified so they can be used to repair, regenerate or replace human tissue.

Somatic-cell medicines:

Contain cells or tissues that have been manipulated to change their biological characteristics or cells or tissues not intended to be used for the same essential functions in the body.

They can be used to cure, diagnose or prevent diseases.

[CAR T Cell Video Link](#)

Why Now?

News

NHS England announces groundbreaking new personalised therapy for children with cancer

📅 5 September 2018

Cancer

Children and young people

Medicine

[Home](#) > [News & Events](#) > [Cancer Currents Blog](#)

FDA Approves Second CAR T-Cell Therapy for Lymphoma

[Subscribe](#)

May 22, 2018, by NCI Staff

On May 1, the Food and Drug Administration (FDA) approved the CAR T-cell therapy [tisagenlecleucel \(Kymriah\)](#) for adults with certain types of [non-Hodgkin lymphoma](#), making it the second CAR T-cell therapy approved for [lymphoma](#) and the second FDA approval for this drug.

Last year, FDA approved another CAR T-cell therapy, [axicabtagene ciloleucel \(Yescarta\)](#), for the treatment of [diffuse large B-cell lymphoma \(DLBCL\)](#). CAR T-cell therapy is a type of [immunotherapy](#) that involves a one-time infusion of a patient's own immune cells that have been



First two CAR-T cell medicines recommended for approval in the European Union

[Share](#)

Press release 29/06/2018

Development of Kymriah and Yescarta supported through PRIME

The European Medicines Agency (EMA) has recommended the first two [marketing authorisations](#) for chimeric antigen receptors (CAR) T-cells medicines in the European Union (EU). Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) are advanced therapies for blood cancer. They belong to a new generation of personalised cancer immunotherapies that are based on collecting and modifying patients' own immune cells to treat their cancer.

Indications of advanced therapy trials




Figure 1: Disease indications of past and current clinical trials as of 31st December 2016. Oncology CAR-T products dominate the field, with regenerative somatic cell therapies comprising a major fraction of trials. Source: Alliance for Regenerative Medicine Data Report 2016.

Pipeline continued





Figure 3: Number of advanced therapy clinical trials worldwide and within EU, stratified by phase. Ethical restrictions prevent advanced therapies from undergoing phase I testing in healthy volunteers. Because early-phase trial subjects are patients, most pilot trials include efficacy endpoints, and are thus categorised as phase I/II trials. The classification of pilot trials as phase II explains the relatively high number of phase II trials compared to phase I. Few advanced therapies have yet reached phase III. Source: Alliance for Regenerative Medicine Data Report 2016.

The scale up challenge

Estimated number of patients in the UK per year

CATAPULT
Cell and Gene Therapy




iMATCH

Innovative Manchester Advanced Therapies Centre Hub

September 2017
Innovate UK and Catapult
launch a call for 3
advanced therapy
treatment centres (ATTC)

Advanced Therapy Treatment Centres



The network of Advanced Therapy Treatment Centres will develop and deliver systems for the delivery of cutting edge cell and gene therapies.

- The network will increase the ability of the NHS to deliver disruptive medicines
- The centres will develop systems and processes within the trusts and hospitals capable of delivering advanced therapies at scale to patients across the NHS
- The learnings and systems from the initial centres will be rolled out to other centres in the UK

iMATCH - Pharmacy Deliverables

1

Governance
Framework

2

Recruitment &
Training

3

Electronic
Prescribing of
ATMPs

Pharmacy Governance



Practicalities

- Cell products are frozen to -160 degrees C
- Stored in Liquid Nitrogen tanks – in nitrogen vapour
- Temperature monitoring required throughout the whole process
- Managed by the Stem Cell Lab team – expertise in handling cells and ensuring correct supply to the ward for the correct patient.

Pharmacy Governance - Locally

Pharmacy delegate handling of CAR T Cells to the Stem Cell Lab
(SOP of delegated duty)



Pharmacy conducted initial lab visit and lab completed a self assessment



Pharmacy Stem Cell Lab Audit Plan in place


- Quarterly visits to monitor all CAR T Cell activity (trials and commissioned)
- Attendance of month combined transplant meeting for non-conformance/deviations to be discussed.
- Annual re-audit and spot check audit on 1 study



Practical Implications for Pharmacy

- Pre-conditioning Chemo
 - Cyclophosphamide and Fludarabine
 - Day -7 and -6
- Prescribing CAR T Cells
 - Range of cells can be prescribed
 - Units such as PFU or VP
 - On iQemo:
 - pharmacist screens,
 - Stem Cell Lab HTA DI releases
- Cytokine Release Syndrome and other toxicities

Toxicities from CAR T Cell Therapy



Tocilizumab – first line treatment for CRS

Tocilizumab

- Dose of 8mg/kg MAX 800mg in a single dose
- Up to 3 doses in one day, 8 hour intervals
- Maximum 4 doses allowed in total
- Given as a 1 hour infusion in 100 ml 0.9% sodium chloride
- Will be made at ward level, using aseptic technique
- Vials and accompanying worksheets to be stored in the emergency cupboard (fridge)



Doses used in clinical trials can from 4-8mg/kg, depending on the clinical trial – trial-specific worksheets will also be available.

Ward training required to ensure understanding of different doses within a clinical trial setting

Open CAR-T Clinical Trials – CALM Study

Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL) CALM study (UCART19 in Advanced Lymphoid Malignancies)

Treatment:

Fludarabine 30mg/m² IV infusion for 3 days over 15/30 minutes from D-7 to D-5.

Cyclophosphamide 500mg/m² IV infusion over 1 hour for 3 days from D-4 to D-2

Alemtuzumab IV 8mg /day for 5 days from D-7 to D-3.

UCART19 cells Day 0

UCART19 dose level	UCART19 dose expressed in number of cells (number of vials)	
	Patient weight < 66 kg	Patient weight ≥ 66 kg
DL-1	6x10 ⁵ cells (1)*	
DL1	6x10 ⁶ cells (1)*	
DL2	6x10 ⁷ cells (3)	8x10 ⁷ cells (4)
DL3	1.8x10 ⁸ cells (9)	2.4x10 ⁸ cells (12)

Open CAR-T Clinical Trials – AUTO-2 Study

A single arm, open label, multicentre, phase I/II study evaluating the safety and clinical activity of AUTO2, a CAR T cell treatment targeting BCMA and TACI in patients with relapsed or refractory multiple myeloma

Treatment:

Fludarabine 30mg/m² IV infusion in 100ml 0.9% sodium chloride over 30 minutes

Cyclophosphamide 300mg/m² IV infusion in 100ml 0.9% sodium chloride over 30 minutes

On days -6, -5, -4

AUTO-1 cells Day 0

Cohort number	Cell dose
1 (Dose level 1)	15×10^6 RQR8/APRIL CAR positive T cells
2 (Dose level 2)	75×10^6 RQR8/APRIL CAR positive T cells
3 (Dose level 3)	225×10^6 RQR8/APRIL CAR positive T cells
4 (Dose level 4)	600×10^6 RQR8/APRIL CAR positive T cells
5 (Dose level 5)	$900-1200 \times 10^6$ RQR8/APRIL CAR positive T cells

Approved Products - Kymriah

NOVARTIS:

Kymriah® (tisagenlecleucel)

Approved indications are for the treatment of:

- paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse;
- adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

Licensed Products – Yescarta

Kite (Gilead):

Yescarta™ (Axicabtagene Ciloleucel)

Approved indications are for the treatment of:

- adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified,
- primary mediastinal large B-cell lymphoma (PMBCL),
- high-grade B-cell lymphoma,
- DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL).

Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.



When do we start?

- Accreditation by JACIE
- Selection by NHS England as a commissioned centre.
 - Payment process still TBC
- Approval from Novartis and Gilead as a site.
 - Site evaluation and training
- Local readiness of all affected departments (including private patients).

Summary

- ATMPs are medicinal products
- Cell therapy products are personalized, high-risk medicines which Pharmacy must have oversight and the overall responsibility rests with the Chief pharmacist.
- Toxicity from cell therapy products is likely – need to understand how to treat and support.
- Each treatment is different.